Algernon Pharmaceuticals Signs Agreement with Charles River Laboratories for DMT Preclinical Studies

UF startup Algernon Pharmaceuticals Inc., formerly known as Breathtec Biomedical, a clinical stage pharmaceutical development company, announced that it has signed an agreement with Charles River Laboratories, an American corporation specializing in a variety of preclinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries, for preclinical studies of AP-188 (N,N-Dimethyltryptamine or DMT) for the company’s stroke clinical research program. Algernon’s preclinical study of DMT will be conducted at the Charles River research facility in Finland.